DDInter1642 DDInter1738
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19 antibodies.[L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling. Its relative ubiquity across different stages of B-cell development, including pre-B and mature B-lymphocytes, as well as its presence in several B-cell malignancies (e.g. chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL)) has made it a desirable target in the treatment these B-cell malignancies. Tafasatimab is designed to bind to and block the activity of the CD19 surface antigen, which ultimately results in the lysis of B-cells (both healthy and malignant). Having previously received Breakthrough Therapy, Fast Track, and Orphan designations from the FDA, tafasatimab-cxix (Monjuvi®) received an accelerated approval on July 31st, 2020, for the treatment of relapsed or refractory DLBCL in adult patients who cannot receive autologous stem cell transplants. It must be used in combination with [lenalidomide], as this combination results in greater efficacy as compared to either agent alone.
Tafasitamab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Tafasitamab {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Tafasitamab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Tafasitamab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Tafasitamab may lead to a major life threatening interaction when taken with Tofacitinib
Tafasitamab may lead to a major life threatening interaction when taken with Upadacitinib